title: Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
abstract: Investigate FasL and survivin expression in a series of primary ovarian surface epithelial tumors, correlate their expression with each other, and characterize the presence of CD3+ T-lymphocytes in studied tumors and determine whether their presence correlates with FasL or survivin expression in malignant cases. FasL and survivin expression was assessed in 54 ovarian epithelial tumors. The results were compared between different tumor types and grades. Correlation between both markers' expression in all studied tumors was done. Either marker's expression was compared to the mean CD3+ T-lymphocytes per HPF in the studied malignant tumors. Either FasL or survivin expression was significantly higher in malignant versus benign ovarian epithelial tumors (p < 0.001 for both) and both markers were strongly correlated to each other (r = 0.877 & p < 0.001). Malignant tumors show significantly higher mean CD3+ T-lymphocytes than benign and borderline tumors. The mean CD3+ T-lymphocytes decrease significantly on increasing malignant tumor grade (p = 0.019) and expression of both FasL and survivin (r = -0.729, -0.582, respectively & p < 0.001 for both). The higher expression of FasL and survivin in malignant as compared to benign ovarian tumors suggest that they have a significant role in pathogenesis of ovarian carcinoma. Both markers are strongly correlated to each other and may contribute to immune escape of ovarian carcinoma as their higher expression is associated with decreased number of CD3 + T-lymphocytes.
authors.affiliation: Pathology Department, Tanta Faculty of Medicine, Tanta, Ghrbia, Egypt. eimanhasby@yahoo.com
authors.forename: Eiman Adel
authors.initials: EA
authors.lastname: Hasby
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D017252:CD3 Complex / Q000378:metabolism*; D018284:Cystadenocarcinoma, Serous / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016889:Endometrial Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D053222:Fas Ligand Protein / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D000077022:Survivin; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
chemical_list: C107489:BIRC5 protein, human; D017252:CD3 Complex; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin